[Epub ahead of print]
Identification of CB1/CB2 Ligands from Zanthoxylum bungeanum.
Source
Biomedical Research Center, National Institute on Aging, National Institutes of Health , 251 Bayview Boulevard, Suite 100, Baltimore, Maryland 21224, United States.
Abstract
In order to study cannabinoid receptor ligands, a novel plate-based assay was developed previously to measure internalization of CB1/CB2 receptors by determining the change in the intracellular levels of the radiolabeled agonists. This plate-based assay was also used for screening against complex matrices, specifically, in the present study screening for CB1/CB2 receptor activity of extracts for several species of the plant genus Zanthoxylum. The objective of this screen was to identify novel antagonists of the CB1 receptor, which simultaneously displayed agonist activity against the CB2 receptor, since compounds matching this criterion could be potential candidates for the treatment of type-1 diabetes. As a result, two Z. bungeanum extracts were deemed active, leading to the identification of eight compounds, of which compound 7 [(2E,4E,8E,10E,12E)-N-isobutyl-2,4,8,10,12-tetradecapentaenamide, γ-sanshool] was obtained as a promising lead compound.
- PMID:
- 24175626
- [PubMed – as supplied by publisher]